seed
Stage
About
P3 Therapeutics develops first-in-class small chemical molecules (SCMs) for chronic immune-mediated inflammatory diseases — notably spondyloarthritis — using a Triple Target Activation (TTA) approach. The company combines AI/ML drug discovery with organ-on-chip biomarker platforms for preclinical testing and offers collaboration and licensing of compounds and biomarkers.
Explore P3 Therapeutics (P3T)'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.